In contrast, between DMBA + ROSI-treated strains, PPARγ-MG KO mice had a ~2-fold higher mammary tumour incidence compared to PPARγ-WTs (53 ± 12 vs. 29 ± 8%, respectively), although this trend was not statistically significant. This evidence concerns the gene PPARG and breast cancer.